Janssen Research & Development, LLC
The purpose of this study is to identify the recommended phase 2 regimen(s) RP2R(s) of pasritamig and combination regimens in Part 1 (dose escalation) and to determine safety at the putative RP2R(s) of pasritamig with the combination regimens in Part 2 (dose expansion).
Inclusion Criteria: * Part 1 A-G, 1I, 1J, and 1K (all combination treatments) and Parts 2B-C (cabazitaxel, docetaxel): Metastatic castration-resistant prostate cancer (mCRPC) with confirmed adenocarcinoma of the prostate as defined by prostate cancer working group 3 (PCWG3); Parts 2D-G, 2I, 2J, and 2K (apalutamide, enzalutamide, darolutamide, abiraterone acetate + prednisone \[AAP\], lutetium Lu-177 vipivotide tetraxetan, JNJ-101556143): mCRPC: Histologically confirmed adenocarcinoma of the prostate as defined by PCWG3, with a minimum PSA of 2 nanogram \[ng\]/milliliter (mL); Part 2H (apaluta…
Pasritamig will be administered.
Cetrelimab will be administered by intravenous infusion.
Cabazitaxel will be administered by intravenous infusion.
Docetaxel will be administered by intravenous infusion.
Apalutamide will be administered orally.
Enzalutamide will be administered orally.
Darolutamide will be administered orally.
Abiraterone acetate plus prednisone (AAP) will be administered orally.
Lutetium Lu-177 vipivotide tetraxetan will be administered intravenously.
JNJ-101556143 will be administered orally.